Get the Stockscreener App
2.22
18.09%
0.34
After Hours:
2.18
-0.04
-1.80%
Pacific Biosciences Of California Inc stock is traded at $2.22, with a volume of 21.15M.
It is up +18.09% in the last 24 hours and up +16.84% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.88
Open:
$1.85
24h Volume:
21.15M
Relative Volume:
2.66
Market Cap:
$670.23M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.48
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+37.89%
1M Performance:
+16.84%
6M Performance:
+126.25%
1Y Performance:
+25.42%
1-Day Range:
$1.8317
$2.235
1-Week Range:
$1.5235
$2.235
52-Week Range:
$0.8511
$2.46
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.22 | 567.59M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
What analysts say about Pacific Biosciences of California Inc stock - earlytimes.in
PacBio Stock Soars: Time to Dive In? - StocksToTrade
Pacific Biosciences of California launches HiFi guide to enhance lab workflows - Traders Union
PacBio’s Regulatory Triumph in China Fuels Market Optimism - timothysykes.com
PacBio’s New Regulatory Approval Fuels Expansion Hopes - timothysykes.com
Pacific Biosciences partners with SPT Labtech to enhance automation - Traders Union
Will Pacific Biosciences of California Inc. (P09) stock beat revenue estimates2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
How higher bond yields impact Pacific Biosciences of California Inc. (P09) stockCEO Change & Consistent Profit Trade Alerts - newser.com
Will Pacific Biosciences of California Inc. stock split again soon2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Will Pacific Biosciences of California Inc. (P09) stock announce special dividendWeekly Trend Report & Daily Chart Pattern Signals - newser.com
Is Pacific Biosciences of California Inc. stock ready for a breakoutProfit Target & Low Risk High Win Rate Stock Picks - newser.com
Price to cash flow ratio of Pacific Biosciences of California, Inc. – HAM:P09 - TradingView
Will Pacific Biosciences of California Inc. stock recover after recent dropJuly 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
Does Pacific Biosciences of California Inc. stock trade at a discount to peers - newser.com
Is Pacific Biosciences of California Inc. stock a top pick in earnings seasonMarket Risk Analysis & Weekly High Potential Alerts - newser.com
Why Pacific Biosciences of California Inc. (P09) stock could be next leaderChart Signals & Real-Time Chart Pattern Alerts - newser.com
Smart tools for monitoring Pacific Biosciences of California Inc.’s price actionCEO Change & Entry Point Strategy Guides - newser.com
Is Pacific Biosciences of California Inc. (P09) stock attractive for dividend growth2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Is Pacific Biosciences of California Inc. (P09) stock at risk of policy regulationPortfolio Growth Summary & Weekly Chart Analysis and Trade Guides - newser.com
Pacific Biosciences of California: Radboud University unveils HiFi sequencing for genetic tests - Traders Union
Price action breakdown for Pacific Biosciences of California Inc.July 2025 Recap & Fast Entry Momentum Alerts - newser.com
Pacific Biosciences of California appoints CFO - MSN
Will Pacific Biosciences of California Inc. continue its uptrendWeekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
How to build a custom watchlist for Pacific Biosciences of California Inc.Market Risk Report & AI Powered Market Trend Analysis - newser.com
Can Pacific Biosciences of California Inc. stock resist market sell offs2025 EndofYear Setup & Community Consensus Trade Alerts - newser.com
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):